Shuya Wu, MD
Allergy & Immunology · Lexington, KYNPI 1982947958
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 415 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,814, 3.1 times the $919 reported in 2019.
Across 415 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$1K
- CSL Behring$1K
- GSK$932
- Regeneron Healthcare Solutions, Inc.$759
- Takeda Pharmaceuticals U.S.A., Inc.$596
- plus $3K from 27 others
What the payments were for
- Consulting fees$220%
- Food & beverage$9,844100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,667 |
| Sanofi | 48 | $1,477 |
| CSL Behring | 52 | $1,130 |
| GSK | 52 | $932 |
| Regeneron Healthcare Solutions, Inc. | 28 | $759 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $596 |
| Genentech USA, Inc. | 22 | $487 |
| Pfizer | 25 | $451 |
| Blueprint Medicines Corporation | 4 | $274 |
| Amgen | 14 | $266 |
| Optinose US, Inc. | 11 | $239 |
| Grifols USA, LLC | 8 | $231 |
| Novartis | 10 | $215 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $194 |
| Pharming Healthcare, Inc. | 8 | $154 |
| Kaleo, Inc. | 7 | $145 |
| Boehringer Ingelheim | 6 | $91 |
| Biocryst US Sales Co., LLC | 5 | $91 |
| Alk-abello, Inc | 3 | $59 |
| Cycle Pharmaceuticals Inc | 2 | $52 |
| Shire North American Group Inc | 2 | $48 |
| Phadia US Inc. | 2 | $45 |
| ADMA Biomanufacturing LLC | 2 | $44 |
| Ionis Pharmaceuticals, Inc. | 2 | $38 |
| Merck | 2 | $32 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Octapharma USA, Inc. | 1 | $22 |
| USWM, LLC | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Covis Pharma GmbH | 1 | $19 |
| Jubilant Hollisterstier LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,878 in reported general payments places this provider in the 60th percentile of 66 allergy & immunology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $150,397 |
| Fasenra PenBenralizumab | 13 | $72,617 |
| XolairOmalizumab | 20 | $54,434 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $25,309 |
| Spiriva RespimatTiotropium Bromide | 25 | $20,938 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $17,538 |
| Arnuity ElliptaFluticasone Furoate | 41 | $12,672 |
| Epinephrine | 22 | $5,827 |
| Ipratropium Bromide | 173 | $5,567 |
| Azelastine Hcl | 123 | $4,412 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $4,157 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $3,834 |
| Fluticasone Propionate HfaFluticasone Propionate | 17 | $3,781 |
| Fluticasone Propionate | 228 | $3,460 |
| Montelukast Sodium | 327 | $3,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $1,130 | $150,39736 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $932 | $55,52096 claims |
| Boehringer IngelheimSpiriva Respimat | $91 | $20,93825 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $5,82722 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $3,83412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 66 allergy & immunology providers in Kentucky.
Other allergy & immunology in Lexington
- Rajiv AroraLexington$144K
- Priya WarrierLexington$93K
- William GreisnerLexington$39K
- Tracie OverbeckLexington$19K
- Shaunah RitterLexington$7K
- Alexander PattersonLexington$6K
- Kelsey CoyleLexington$3K
- Amy MashburnLexington$2K
- Leslie BranchLexington$1K
- John ThompsonLexington$258
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.